Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q1 FY22 results · Apr–Jun 2021
Suven Life Sciences reported revenue from operations of ₹2.01 crore (up 40.4% from Q1 FY21) and net loss of ₹39.21 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.01 | 1.43 | +40.4% | 1.56 | +28.8% |
| Other income | 4.56 | 2.53 | +80.1% | 1.32 | +244.3% |
| Total income | 6.56 | 3.96 | +65.8% | 2.88 | +127.8% |
| Profit before tax | (39.21) | (12.96) | Loss widened | (21.57) | Loss widened |
| Net profit for the period | (39.21) | (10.49) | Loss widened | (21.61) | Loss widened |
| EPS, basic (₹) | (3.08) | (0.82) | Loss widened | (1.70) | Loss widened |
| Net margin (%) | -1954.5 | -734.2 | -1388.0 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2.01 | 1.43 | +40.4% | 1.56 | +28.8% |
| Other income | 4.56 | 2.53 | +80.1% | 1.32 | +244.3% |
| Total income | 6.56 | 3.96 | +65.8% | 2.88 | +127.8% |
| Profit before tax | (8.49) | (6.54) | Loss widened | (8.46) | Loss widened |
| Net profit for the period | (8.49) | (4.08) | Loss widened | (8.51) | Loss narrowed |
| EPS, basic (₹) | (0.67) | (0.32) | Loss widened | (0.67) | Unchanged |
| Net margin (%) | -423.4 | -285.4 | -546.4 |
Consolidated
- Filed with BSE
- 10 Aug 2021, 11:28 IST
- Board meeting
- 09 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2021, 11:28 IST
- Board meeting
- 09 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE